Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 3/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 7/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5927175 | 0.94 | ITGB1 (0.47) | CA2BCL2BCL2L1MCL1ITGB1 | |
| SCHEMBL5926979 | 0.88 | CTSA (0.41) | CCR3 | |
| SCHEMBL5926531 | 0.83 | ITGB1 (0.51) | CA2MCL1ITGB1ITGA4ITGB7 | |
| SCHEMBL5926498 | 0.82 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL5927179 | 0.81 | CTSA (0.45) | — | |
| SCHEMBL5926611 | 0.80 | MMP1 (0.51) | CA2ITGB1ITGA4ITGB7MMP2 | |
| SCHEMBL5926711 | 0.79 | ITGB1 (0.50) | CA2ITGB1ITGA4ITGB7MMP2 | |
| SCHEMBL5926499 | 0.79 | ITGB1 (0.47) | CA2ITGB1ITGA4ITGB7MMP2 | |
| SCHEMBL8337901 | 0.79 | ITGB1 (0.47) | CA2ITGB1ITGA4ITGB7MMP2 | |
| SCHEMBL8337871 | 0.79 | KEAP1 (0.45) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CA2 4187/4885BCL2 2041/4885BCL2L1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.